Get the Daily Brief
Latest Biotech News
Viking Therapeutics Oral Obesity Drug Achieves Weight Loss but Faces High Discontinuations
Viking Therapeutics' oral GLP-1/GIP agonist VK-2735 demonstrated up to 12.2% weight loss in a phase 2 trial after 13 weeks. However, high gastrointestinal adverse events led to a 38%...
CSL Outlines Restructuring: Workforce Cuts and Seqirus Vaccine Unit Spin-Off
Australian pharmaceutical company CSL announced a strategic overhaul including a workforce reduction of up to 15% and the spin-off of its influenza vaccine business, Seqirus, into an independent...
Natera’s Signatera Test Identifies Bladder Cancer Patients Benefiting from Tecentriq Therapy
In the Phase III IMvigor011 trial, Natera’s Signatera circulating tumor DNA (ctDNA) test successfully stratified muscle-invasive bladder cancer patients regarding response to Genentech's Tecentriq...
VantAI and Halda Therapeutics Forge $1B+ Collaboration to Develop Proximity-Based Therapies
VantAI, an AI-driven protein interaction company spun out from Roivant Sciences, partnered with Halda Therapeutics in a deal exceeding $1 billion in potential value to accelerate discovery of...
Viking Therapeutics Oral Obesity Drug Faces Investor Concerns
Viking Therapeutics reported weight loss of up to 12.2% in a phase 2 trial of its oral GLP-1/GIP agonist VK-2735 after 13 weeks but was met with investor disappointment due to substantial...
Novo Nordisk’s Wegovy Expands to Fatty Liver Disease Treatment
The U.S. Food and Drug Administration granted accelerated approval for Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) to treat metabolic dysfunction-associated steatohepatitis (MASH), a common...
Adaptive Biotechnologies and Genentech End Cancer Cell Therapy Collaboration
Adaptive Biotechnologies announced termination of its strategic partnership and licensing agreement with Genentech for developing personalized cancer cell therapies, effective February 2026. The...
FDA Delays and Rejections Impact Rare Disease and Gene Therapy Development
The FDA has delayed decisions on Regenxbio’s Hunter syndrome gene therapy and rejected PTC Therapeutics’ Friedreich’s ataxia drug vatiquinone, requesting further well-controlled studies. Stealth...
AI-Driven Innovations in Drug Delivery and Diagnostics
Researchers are advancing AI applications to accelerate RNA therapy development, improve mammogram interpretations, and design novel diagnostic platforms. MIT’s COMET model optimizes lipid...
Gene Editing and T-Cell Therapy Advances Against Cancer
Anocca AB raised $46 million to fund a phase I trial testing its CRISPR-edited T-cell receptor therapy targeting KRAS mutations in pancreatic cancer. Skyhawk Therapeutics secured a $2 billion...
Neurological and Neurodegenerative Disease Research and Therapeutics
Multiple studies highlight advances in understanding and treating neurodegenerative diseases. A new activator DNL343 targets eIF2B to address ALS and TDP-43 proteinopathies. Novel gene therapies...
Stem Cell Applications in Disease and Space Research
Innovations in stem cell science continue with several breakthroughs. Tel Aviv University researchers are preparing for the first human transplant of lab-grown spinal cord stem cells aimed at...
Biomanufacturing and Industry Restructuring in Biotech and Pharma
CSL announced restructuring plans including a 15% workforce reduction and spinning off its Seqirus vaccine unit into a standalone company to improve capital efficiency and strategic focus....
Viking’s Oral Obesity Drug Faces Investor Setbacks Amid Trial Discontinuations
Viking Therapeutics recently announced phase 2 data for its oral GLP-1/GIP receptor dual agonist VK-2735, demonstrating significant weight loss of up to 12.2% over 13 weeks. Despite meeting...
PTC Therapeutics’ Friedreich’s Ataxia Drug Rejected by FDA
The FDA issued a complete response letter denying approval for PTC Therapeutics’ vatiquinone to treat Friedreich’s ataxia, citing insufficient evidence of efficacy despite positive secondary...
Novo Nordisk’s Wegovy Approved for Metabolic Fatty Liver Disease
Novo Nordisk’s GLP-1 agonist Wegovy received accelerated FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults with non-cirrhotic liver scarring. Phase 3 results...
Skyhawk Therapeutics Teams with Merck KGaA in $2 Billion RNA Drug Deal
Skyhawk Therapeutics announced a major neurology-focused collaboration with Germany’s Merck KGaA aimed at discovering RNA splicing modulators. The deal could be valued up to $2 billion and expands...
Anocca Secures $46 Million for Novel Pancreatic Cancer T-Cell Therapy Trial
Anocca AB has raised $46 million to advance its CRISPR-edited T-cell receptor (TCR) immunotherapy targeting mutant KRAS mutations in pancreatic ductal adenocarcinoma, one of the most aggressive...
Adaptive Biotechnologies and Genentech End Cancer Cell Therapy Collaboration
Adaptive Biotechnologies and Genentech announced termination of their strategic collaboration initiated in 2018 to develop personalized cancer cell therapies using T-cell receptor technologies....
AI Model Accelerates Design of Nanoparticles for RNA Therapeutics
Researchers at MIT developed COMET, a transformer-based machine learning model, to optimize lipid nanoparticle (LNP) formulations for RNA vaccine and therapy delivery. By analyzing thousands of...